NDAORALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DAYPRO ALTA (oxaprozin potassium) by Pfizer is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2002.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYPRO ALTA is an oral nonsteroidal anti-inflammatory drug (NSAID) containing oxaprozin potassium that provides analgesic, anti-inflammatory, and antipyretic effects. It works by inhibiting cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis, thereby decreasing pain and inflammation. The potassium salt formulation enables rapid onset compared to standard oxaprozin.
LOE Approaching
LOE-approaching lifecycle with moderate competitive pressure (30%) signals contraction in brand team headcount and shift toward defensive positioning.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of oxaprozin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Oxaprozin is a potent inhibitor of prostaglandin synthesis in vitro. Oxaprozin…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching lifecycle indicate limited career growth on DAYPRO ALTA; roles focus on defending market share and managing generic transition rather than expansion. Professionals should view this asset as defensive portfolio management with emphasis on operational efficiency and cost containment.
Brand Manager
Worked on DAYPRO ALTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.